Skip to main content
Erschienen in: Discover Oncology 1/2010

01.02.2010

Mouse Prostate Cancer Cell Lines Established from Primary and Postcastration Recurrent Tumors

verfasst von: Chun-Peng Liao, Mengmeng Liang, Michael B. Cohen, Andrea Flesken-Nikitin, Joseph H. Jeong, Alexander Y. Nikitin, Pradip Roy-Burman

Erschienen in: Discover Oncology | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

The clinical course of prostate cancer is grouped into two broad phases. The first phase, which is the growth of the androgen-dependent cancer (AD-Ca), responds well to androgen depletion treatment while the second phase that could be termed as androgen-depletion-independent cancer (ADI-Ca) does not. We used two separate prostate tumors, one AD-Ca and one ADI-Ca from the conditional Pten deletion mouse model, to generate from each a pair of cell lines. The AD-Ca cell lines (E2 and E4) and the ADI-Ca cell lines (cE1 and cE2) display biallelic deletion at the Pten gene locus, an event which is specific for the prostate epithelium for this mouse model and a fairly similar level of expression of the androgen receptor (AR). The ADI-Ca cell lines (cE series) grow well in the absence of androgen, display increased AR transcription under androgen-deprived environment, and retain the sensitivity to increased proliferation when androgen is supplemented. The AD-Ca cell lines (E series) grow slowly in the absence of androgen and, unlike cE cells, do not show increased AR expression when maintained in the absence of androgen. The detection of epithelial cell markers, such as CK8, CK14, CK18, and E-cadherin in the cE series is conforming with the polygonal epithelial morphology of these cells in culture. The E cells also present mostly polygonal-shaped morphology with a small percent of cells with fibroblastoid morphology and produce little or very low levels of cytokeratins but increased levels of vimentin, Twist, and Slug, the markers known to be associated with epithelial–mesenchymal transition. Each of the cell lines, when inoculated subcutaneously into male or female NOD.SCID mice induced tumors within 8 weeks with 100% incidence. Histopathological examinations of the tumor sections, however, led to noticeable biological differences. The cE series engenders adenocarcinomas, particularly in male hosts, and the E series induces sarcomatoid carcinomas (positively stained for CK8 and AR as well as vimentin expression) in either male or female hosts. These new cell lines are promising models for the elucidation of the androgen metabolism and their role in prostate cancer.
Literatur
1.
2.
Zurück zum Zitat Bonkhoff H, Berges R (2009) From pathogenesis to prevention of castration resistant prostate cancer. Prostate 70:100–112CrossRef Bonkhoff H, Berges R (2009) From pathogenesis to prevention of castration resistant prostate cancer. Prostate 70:100–112CrossRef
3.
Zurück zum Zitat Roy-Burman P, Tindall DJ, Robins DM et al (2005) Androgens and prostate cancer: are the descriptors valid? Cancer Biol Ther 4:4–5PubMed Roy-Burman P, Tindall DJ, Robins DM et al (2005) Androgens and prostate cancer: are the descriptors valid? Cancer Biol Ther 4:4–5PubMed
4.
Zurück zum Zitat Brooke GN, Bevan CL (2009) The role of androgen receptor mutations in prostate cancer progression. Curr Genomics 10:18–25CrossRefPubMed Brooke GN, Bevan CL (2009) The role of androgen receptor mutations in prostate cancer progression. Curr Genomics 10:18–25CrossRefPubMed
5.
Zurück zum Zitat Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T (2001) Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61:3550–3555PubMed Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T (2001) Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61:3550–3555PubMed
6.
Zurück zum Zitat Waltering KK, Helenius MA, Sahu B et al (2009) Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 69:8141–8149CrossRefPubMed Waltering KK, Helenius MA, Sahu B et al (2009) Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 69:8141–8149CrossRefPubMed
7.
Zurück zum Zitat Chen Y, Clegg NJ, Scher HI (2009) Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 10:981–991CrossRefPubMed Chen Y, Clegg NJ, Scher HI (2009) Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 10:981–991CrossRefPubMed
8.
Zurück zum Zitat Roy-Burman P, Wu H, Powell WC, Hagenkord J, Cohen MB (2004) Genetically defined mouse models that mimic natural aspects of human prostate cancer development. Endocr Relat Cancer 11:225–254CrossRefPubMed Roy-Burman P, Wu H, Powell WC, Hagenkord J, Cohen MB (2004) Genetically defined mouse models that mimic natural aspects of human prostate cancer development. Endocr Relat Cancer 11:225–254CrossRefPubMed
9.
Zurück zum Zitat Abate-Shen C, Brown PH, Colburn NH et al (2008) The untapped potential of genetically engineered mouse models in chemoprevention research: opportunities and challenges. Cancer Prev Res (Phila Pa) 1:161–166 Abate-Shen C, Brown PH, Colburn NH et al (2008) The untapped potential of genetically engineered mouse models in chemoprevention research: opportunities and challenges. Cancer Prev Res (Phila Pa) 1:161–166
10.
Zurück zum Zitat Trotman LC, Niki M, Dotan ZA et al (2003) Pten dose dictates cancer progression in the prostate. PLoS Biol 1:385–396CrossRef Trotman LC, Niki M, Dotan ZA et al (2003) Pten dose dictates cancer progression in the prostate. PLoS Biol 1:385–396CrossRef
11.
Zurück zum Zitat Ma X, Ziel-van der Made AC, Autar B et al (2005) Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res 65:5730–5739CrossRefPubMed Ma X, Ziel-van der Made AC, Autar B et al (2005) Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res 65:5730–5739CrossRefPubMed
12.
Zurück zum Zitat Zhou Z, Flesken-Nikitin A, Corney DC et al (2006) Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res 66:7889–7898CrossRefPubMed Zhou Z, Flesken-Nikitin A, Corney DC et al (2006) Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res 66:7889–7898CrossRefPubMed
13.
Zurück zum Zitat Bruxvoort KJ, Charbonneau HM, Giambernardi TA et al (2007) Inactivation of Apc in the mouse prostate causes prostate carcinoma. Cancer Res 67:2490–2496CrossRefPubMed Bruxvoort KJ, Charbonneau HM, Giambernardi TA et al (2007) Inactivation of Apc in the mouse prostate causes prostate carcinoma. Cancer Res 67:2490–2496CrossRefPubMed
14.
Zurück zum Zitat Wang S, Gao J, Lei Q et al (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4:209–221CrossRefPubMed Wang S, Gao J, Lei Q et al (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4:209–221CrossRefPubMed
15.
Zurück zum Zitat Liao CP, Zhong C, Saribekyan G et al (2007) Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res 67:7525–7533CrossRefPubMed Liao CP, Zhong C, Saribekyan G et al (2007) Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res 67:7525–7533CrossRefPubMed
16.
Zurück zum Zitat van Bokhoven A, Varella-Garcia M, Korch C et al (2003) Molecular characterization of human prostate carcinoma cell lines. Prostate 57:205–225CrossRefPubMed van Bokhoven A, Varella-Garcia M, Korch C et al (2003) Molecular characterization of human prostate carcinoma cell lines. Prostate 57:205–225CrossRefPubMed
17.
Zurück zum Zitat Navone NM, Olive M, Ozen M et al (1997) Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 3:2493–2500PubMed Navone NM, Olive M, Ozen M et al (1997) Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 3:2493–2500PubMed
18.
Zurück zum Zitat Chen ME, Lin SH, Chung LW, Sikes RA (1998) Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens. J Biol Chem 273:17618–17625CrossRefPubMed Chen ME, Lin SH, Chung LW, Sikes RA (1998) Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens. J Biol Chem 273:17618–17625CrossRefPubMed
19.
Zurück zum Zitat Ishikura N, Kawata H, Nishimoto A, Nakamura R, Ishii N, Aoki Y (2009) Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10. Prostate (in press) Ishikura N, Kawata H, Nishimoto A, Nakamura R, Ishii N, Aoki Y (2009) Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10. Prostate (in press)
20.
Zurück zum Zitat Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM (1997) Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 57:3325–3330PubMed Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM (1997) Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 57:3325–3330PubMed
21.
Zurück zum Zitat Jiao J, Wang S, Qiao R et al (2007) Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res 67:6083–6091CrossRefPubMed Jiao J, Wang S, Qiao R et al (2007) Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res 67:6083–6091CrossRefPubMed
22.
Zurück zum Zitat Choi J, Burns AA, Williams RM et al (2007) Core–shell silica nanoparticles as fluorescent labels for nanomedicine. J Biomed Opt 12:1–12 Choi J, Burns AA, Williams RM et al (2007) Core–shell silica nanoparticles as fluorescent labels for nanomedicine. J Biomed Opt 12:1–12
23.
Zurück zum Zitat Wu X, Wu J, Huang J et al (2001) Generation of a prostate epithelial cell specific Cre transgenic mouse model for tissue specific gene ablation. Mech Dev 101:61–69CrossRefPubMed Wu X, Wu J, Huang J et al (2001) Generation of a prostate epithelial cell specific Cre transgenic mouse model for tissue specific gene ablation. Mech Dev 101:61–69CrossRefPubMed
24.
Zurück zum Zitat Leong KG, Wang BE, Johnson L, Gao WQ (2008) Generation of a prostate from a single adult stem cell. Nature 456:804–808CrossRefPubMed Leong KG, Wang BE, Johnson L, Gao WQ (2008) Generation of a prostate from a single adult stem cell. Nature 456:804–808CrossRefPubMed
25.
Zurück zum Zitat Nagy A, Gertsenstein M, Vintersten K, Behringer R (2003) Manipulating the mouse embryo. A laboratory manual, 3rd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, p 389 Nagy A, Gertsenstein M, Vintersten K, Behringer R (2003) Manipulating the mouse embryo. A laboratory manual, 3rd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, p 389
26.
Zurück zum Zitat Leiblich A, Cross SS, Catto JW, Pesce G, Hamdy FC, Rehman I (2007) Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A. Prostate 67:1761–1769CrossRefPubMed Leiblich A, Cross SS, Catto JW, Pesce G, Hamdy FC, Rehman I (2007) Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A. Prostate 67:1761–1769CrossRefPubMed
27.
Zurück zum Zitat Zhou Z, Flesken-Nikitin A, Nikitin AY (2007) Prostate cancer associated with p53 and Rb deficiency arises from the stem/progenitor cell-enriched proximal region of prostatic ducts. Cancer Res 67:5683–5690CrossRefPubMed Zhou Z, Flesken-Nikitin A, Nikitin AY (2007) Prostate cancer associated with p53 and Rb deficiency arises from the stem/progenitor cell-enriched proximal region of prostatic ducts. Cancer Res 67:5683–5690CrossRefPubMed
28.
Zurück zum Zitat Isayeva T, Chanda D, Kallman L, Eltoum IE, Ponnazhagan S (2007) Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Cancer Res 67:5789–5797CrossRefPubMed Isayeva T, Chanda D, Kallman L, Eltoum IE, Ponnazhagan S (2007) Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Cancer Res 67:5789–5797CrossRefPubMed
29.
Zurück zum Zitat Tran CP, Lin C, Yamashiro J, Reiter RE (2002) Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res 1:113–121PubMed Tran CP, Lin C, Yamashiro J, Reiter RE (2002) Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res 1:113–121PubMed
30.
Zurück zum Zitat Hansel DE, Herawi M, Montgomery E, Epstein JI (2007) Spindle cell lesions of the adult prostate. Mod Pathol 20:148–158CrossRefPubMed Hansel DE, Herawi M, Montgomery E, Epstein JI (2007) Spindle cell lesions of the adult prostate. Mod Pathol 20:148–158CrossRefPubMed
31.
Zurück zum Zitat Shappell SB, Thomas GV, Roberts RL et al (2004) Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 64:2270–2305CrossRefPubMed Shappell SB, Thomas GV, Roberts RL et al (2004) Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 64:2270–2305CrossRefPubMed
32.
Zurück zum Zitat Chen CD, Welsbie DS, Tran C et al (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33–39CrossRefPubMed Chen CD, Welsbie DS, Tran C et al (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33–39CrossRefPubMed
33.
Zurück zum Zitat Yuan X, Li T, Wang H et al (2006) Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells. Am J Pathol 169:682–696CrossRefPubMed Yuan X, Li T, Wang H et al (2006) Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells. Am J Pathol 169:682–696CrossRefPubMed
34.
Zurück zum Zitat He W, Dai C, Li Y, Zeng G, Monga SP, Liu Y (2009) Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol 20:765–776CrossRefPubMed He W, Dai C, Li Y, Zeng G, Monga SP, Liu Y (2009) Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol 20:765–776CrossRefPubMed
Metadaten
Titel
Mouse Prostate Cancer Cell Lines Established from Primary and Postcastration Recurrent Tumors
verfasst von
Chun-Peng Liao
Mengmeng Liang
Michael B. Cohen
Andrea Flesken-Nikitin
Joseph H. Jeong
Alexander Y. Nikitin
Pradip Roy-Burman
Publikationsdatum
01.02.2010
Verlag
Springer-Verlag
Erschienen in
Discover Oncology / Ausgabe 1/2010
Print ISSN: 1868-8497
Elektronische ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-009-0005-y

Weitere Artikel der Ausgabe 1/2010

Discover Oncology 1/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.